Benzocaine is a potent ester-type local anesthetic used topically for its rapid onset of action to relieve pain and itching associated with various conditions. At a 20% w/w concentration, it is considered a high-strength formulation primarily intended for short-term use on intact skin or accessible mucous membranes. It acts by reversibly blocking nerve conduction in the sensory neurons, preventing the generation and propagation of action potentials.
Adult: Apply a thin layer to the affected area up to 3-4 times daily. Use the smallest amount necessary to relieve symptoms. Do not apply over large areas.
Note: 1. Clean and dry the affected area. 2. Apply a thin film and rub gently. 3. Wash hands immediately after application unless hands are the treated area. 4. Do not bandage or wrap the area tightly unless directed by a doctor (occlusion increases absorption). 5. For oral mucous membranes, apply directly to the sore area using a cotton swab. Do not swallow. 6. Avoid contact with eyes.
Benzocaine diffuses across the neuronal membrane in its uncharged, lipid-soluble base form. Inside the neuron, it re-equilibrates to its charged cationic form, which binds reversibly to specific receptors on the voltage-gated sodium channels from the intracellular side. This binding inhibits the conformational changes necessary for channel activation, thereby stabilizing the neuronal membrane and blocking the influx of sodium ions. This prevents the depolarization phase of the action potential, halting nerve impulse generation and propagation, leading to a loss of sensation (anesthesia) in the localized area.
Pregnancy: Category C (US FDA). Animal reproduction studies have not been conducted. It is not known whether Benzocaine can cause fetal harm when used topically in small amounts. Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. Avoid large doses or long-term use.
Driving: Unlikely to affect driving ability when used topically as directed. However, systemic absorption leading to dizziness or CNS effects could impair abilities.
| Sulfonamide Antibiotics (e.g., Sulfamethoxazole) | Theoretical cross-allergenicity as both are PABA derivatives. May increase risk of hypersensitivity reactions. | Moderate |
| Other Topical Local Anesthetics (e.g., Lidocaine, Prilocaine) | Additive toxic effects if applied concurrently, increasing risk of systemic absorption and toxicity. | Major |
| Cholinesterase Inhibitors (e.g., Neostigmine, Pyridostigmine) | May competitively inhibit the metabolism (hydrolysis) of Benzocaine, potentially increasing its duration and toxicity. | Moderate |
| Drugs inducing Methemoglobinemia (e.g., Dapsone, Nitrates, Nitroprusside, Primaquine) | Additive risk of developing methemoglobinemia. | Major |
Same composition (Benzocaine (20% w/w)), different brands: